Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABT-981 versus placebo in erosive hand osteoarthritis
NL-OMON42110Phase 2Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Sep 2015
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in erosive hand osteoarthritis (EHOA) comparing ABT-981 with Placebo (2 arms). Primary endpoint: Change from baseline in AUSCAN NR3.1 pain subdomain score at Week 16. Started Sep 2015; status: active, not recruiting.
02
Drugs
lutikizumab
03
Conditions
erosive hand osteoarthritis (EHOA)
Beyond the preview
Go deeper on NL-OMON42110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42110.